Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ROUTINE

Financiado

Cerrado

ROutine diagnostic tool for Urinary Tract INfections caused by Esbl and carbapen...

ROutine diagnostic tool for Urinary Tract INfections caused by Esbl and carbapenamase producing bacteria Treatment of Urinary Tract Infections (UTI) is currently initiated empirically because conventional diagnosis takes 2-3 days from sample to results. Moreover, the pharmaceutical pipeline is almost dry. Therefore, the last decade h... ver más

29/02/2016

KTH

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

KUNGLIGA TEKNISKA HOEGSKOLAN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 5 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-02-29 No tenemos la información de la convocatoria

0% 78% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

5 Participantes

KTH

0.00€ | Lider

MICROFLUIDIC

N.D. | Participante

UANTWERPEN

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

AntibioDx AntibioDx A groundbreaking in vitro diagnostic device with... 71K€ Cerrado

QuickMIC QuickMIC an ultra rapid diagnostic system for Antibiotic... 71K€ Cerrado

ResisTEST Developing a rapid diagnostic kit for antibiotic resistance 150K€ Cerrado

Biotrack-MED Diagnostics device for rapid identification and antibiotics... 71K€ Cerrado

C4L Chips for Life 4M€ Cerrado

FAST-bact A novel fast test for antibiotic susceptibility testing for... 4M€ Cerrado

Líder del proyecto

KUNGLIGA TEKNISKA HOEGSKOLAN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Treatment of Urinary Tract Infections (UTI) is currently initiated empirically because conventional diagnosis takes 2-3 days from sample to results. Moreover, the pharmaceutical pipeline is almost dry. Therefore, the last decade has globally witnessed a huge explosion of antibiotic (AB) resistance in Gram Negative Bacteria (GNB), which has drastically reduced the available AB therapy choices for UTI. The WHO considers this one of the major public health threats. Rapid detection of bacterial species and their AB susceptibility provides the main option to curb this development and prolong the lifetime of currently available antibiotics. In ROUTINE, 3 SMEs and 2 Universities will develop a prototype benchtop instrument that will rapidly (< 30 min) detect bacteria and characterize key antibiotics resistance profiles of ESBL (extended spectrum beta lactamase) and carbapenemase producing GNB directly from the patient urine at the point of care in outpatients and hospitals at a low cost (~20 €/test) and with near 100% sensitivity and specificity. Key factors to success are: 1. The consortium has an established collaboration through other projects 2. The starting point, builds on previous knowhow and the reader, cartridge and bioassay technologies developed within previous collaborations. 3. The uncomplicated raw urine sample material and the choice of technologies will ensure reaching the ground-breaking end goals in terms of assay time, cost, sensitivity, specificity and ease-of-use. 4. The designs, materials and processes used are familiar to regulatory authorities, which enable approval by e.g. FDA. 5. The 3 SMEs have experience in developing and bringing diagnostics products to the market. The project will lead to 1) a complete, tested, POC system, and 2) a tailor-made software algorithm for detection of AB resistant GNB, delivering a revolutionary tool in patient treatment, reducing morbidity and mortality, and curbing the spread of AB resistance.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores